 3. Subject must not have known untreated brain or meningeal metastases. CT scans are not required to rule out brain or meningeal metastases unless there is a clinical suspicion of central nervous system disease. Subjects with treated brain metastases that are radiographically or clinically stable for at least 4 weeks after therapy and have no evidence of cavitation or hemorrhage in the brain lesions are eligible, provided that they are asymptomatic and do not require corticosteroids must have discontinued steroids at least 4 weeks prior to start of rSIFN-co administration. 